OHSU in the news

Tree crashes onto SUV traveling to Doernbecher Children's Hospital

KGW-TV December 12, 2023
A tree at Terwilliger Boulevard and Condor Lane fell on an SUV, smashing the vehicle. The driver, who was headed to the Doernbecher Children's Hospital to visit their child, was able to safely exit the vehicle, and Portland Fire took them to them to Doernbecher.

OHSU privatizing fertility services as San Francisco company opens clinic in Portland

The Lund Report December 12, 2023
The Lund Report interviews Desiree McCue, D.N.P., M.B.A., RN, about the OHSU Department of Obstetrics and Gynecology's decision to “lease” the services of five fertility specialists to Spring Fertility under a physicians services agreement; the company opens a clinic in Northwest Portland on April 1, 2024.

Bio Ascend, a Vaniam Group Company, Reconvenes Inaugural Class of the "Academy of Next Wave of Investigators™" in CLL and NHL

PR Newswire December 11, 2023
Titas Banerjee, M.D., a hematology-oncology fellow in the OHSU Knight Cancer Institute, was included in the inaugural class of Bio Ascend’s “Academy of Next Wave of Investigators” at a networking reception during the ASH meeting. The clinical investigators are participating in a year-long opportunity to engage in live and virtual career development seminars with international thought leaders in the fields of chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

How long it takes to get ill after catching flu – and 10 early signs that suggest you’re about to be struck down

The Sun (UK) December 11, 2023
In an article about how soon flu symptoms appear after exposure and what those symptoms look like, Marcel Curlin, M.D., advises getting the flu vaccine and masking or isolating if exposed: “If I were in contact with someone in the community or elsewhere with a flu ... I would probably wear a mask all the time, and be very careful to wash my hands and not get too close to people.”

Though many jail inmates have addiction problems, facilities lack treatment services

Oregon Capital Chronicle December 11, 2023
In an Oregon Capital Chronicle article about a lack of addiction treatment services in jails — despite the fact that many inmates have substance use disorder problems — Dan Hoover, M.D., discusses his recent study and says, “Incarceration could be a chance to be starting people on these evidence-based medicines, and we’re basically missing that chance.”

New Data Show Novel mt-sRNA Test as Viable Alternative to Other Noninvasive CRC Screening

Gastroenterology & Endoscopy News December 11, 2023
A novel stool test for colorectal cancer screening achieved a sensitivity of 94% for colorectal cancer screening. David Lieberman, M.D., says: “The test demonstrated high sensitivity and specificity across all age groups, with significant improvement in sensitivity for colorectal neoplasia when compared to a FIT [fecal immunochemical test]. The mt-sRNA test met its primary end points and is being considered for approval by the FDA.”

Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome

OncLive December 10, 2023
Arpita Gandhi, M.D., presents results from a Phase IB clinical trial studying stem cell therapy Orca-T, a type of blood cancer therapy that is made of donor stem and immune cells. The study found promising efficacy and safety outcomes for patients with intermediate to high-risk myelodysplastic syndrome. Gandhi says: “Orca-T demonstrated promising results in this high-risk MDS patient population, including high RFS, low incidence of GVHD and very high OS at one year.”

Orca-T Yields Promising RFS/OS in Intermediate or High-Risk MDS

Cancer Network December 10, 2023
Arpita Gandhi, M.D., presents results from a Phase IB clinical trial studying stem cell therapy Orca-T, a type of blood cancer therapy that is made of donor stem and immune cells. The study found promising efficacy and safety outcomes for patients with intermediate to high-risk myelodysplastic syndrome. Gandhi says: “Orca-T demonstrated promising results in this high-risk MDS patient population, including high RFS, low incidence of GVHD and very high OS at one year."

Orca-T Shows Promise in Intermediate-/High-Risk MDS

Cure Today December 10, 2023
Arpita Gandhi, M.D., presents results from a Phase IB clinical trial studying stem cell therapy Orca-T, a type of blood cancer therapy that is made of donor stem and immune cells. The study found promising efficacy and safety outcomes for patients with intermediate to high-risk myelodysplastic syndrome. Gandhi says: “Orca-T demonstrated promising results in this high-risk MDS patient population, including high RFS, low incidence of GVHD and very high OS at one year.”
See more stories